This article is more than 5 years old. Information may no longer be current.
aap Implantate AG partners with global firm to market bone matrix product
Click Here to Manage Email Alerts
aap Implantate AG announced it has licensed one of its proprietary injectable bone matrix products to a leading medical technology company to market the product outside the United States, according to a press release. aap Implantate, based in Berlin, will retain the U.S. rights.
The bone matrix material, available in paste form consisting of 100% synthetic, nanoparticular, phase-pure hydroxylapatite, is intended for use in orthopaedic, trauma, and neurosurgery procedures to fill and reconstruct bone defects. It can also be used with autograft or allograft as a bone graft extender, according to the release.
“We have found an ideal partner with a large global sales and marketing organization to drive increased sales of this unique injectable bone matrix product. As the manufacturer of the product, aap will benefit from this growth while focusing on our core trauma and bone cement businesses,” Biense Visser, chief executive officer of aap Implantate, stated in the release. “The revenue from this license agreement will strengthen aap’s financial base and will be used to support the worldwide marketing of our LOQTEQ product family.”